Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
42.56
-1.09 (-2.50%)
Nov 21, 2024, 4:00 PM EST - Market closed
Avidity Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Cash & Equivalents | 370.19 | 185.08 | 340.4 | 320.45 | 321.46 | 94.58 | Upgrade
|
| Short-Term Investments | 1,218 | 410.27 | 270.33 | 85.1 | 6.68 | - | Upgrade
|
| Cash & Short-Term Investments | 1,589 | 595.35 | 610.73 | 405.54 | 328.14 | 94.58 | Upgrade
|
| Cash Growth | 192.78% | -2.52% | 50.59% | 23.59% | 246.95% | 2960.78% | Upgrade
|
| Accounts Receivable | - | 1.11 | 2.36 | 0.9 | 1.2 | 0.8 | Upgrade
|
| Other Receivables | 19.21 | 7.52 | 1.51 | - | - | - | Upgrade
|
| Receivables | 19.21 | 8.62 | 3.88 | 0.9 | 1.2 | 0.8 | Upgrade
|
| Prepaid Expenses | 14.06 | 7.33 | 8.34 | 4.7 | 2.34 | 0.3 | Upgrade
|
| Total Current Assets | 1,622 | 611.31 | 622.94 | 411.14 | 331.68 | 95.68 | Upgrade
|
| Property, Plant & Equipment | 15.79 | 16.65 | 15.01 | 15.59 | 1.92 | 0.63 | Upgrade
|
| Other Long-Term Assets | 3.11 | 0.6 | 0.85 | 0.85 | 0.3 | 0.6 | Upgrade
|
| Total Assets | 1,641 | 628.56 | 638.8 | 427.58 | 333.9 | 96.91 | Upgrade
|
| Accounts Payable | 7.66 | 8.81 | 4.64 | 2.81 | 7.75 | 2.31 | Upgrade
|
| Accrued Expenses | 60.21 | 39.87 | 39.13 | 20.22 | 3.15 | 1.31 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | - | 2.77 | Upgrade
|
| Current Portion of Leases | 3.8 | 3.64 | 3.11 | 1.77 | - | - | Upgrade
|
| Current Unearned Revenue | 19.66 | 28.37 | 5.04 | 4.86 | 3.69 | 3.84 | Upgrade
|
| Total Current Liabilities | 91.33 | 80.68 | 51.91 | 29.66 | 14.59 | 10.24 | Upgrade
|
| Long-Term Debt | - | - | - | - | - | 1.77 | Upgrade
|
| Long-Term Leases | 3.8 | 6.21 | 7.58 | 9.96 | 0.94 | 0.39 | Upgrade
|
| Long-Term Unearned Revenue | 42.26 | 40.9 | 1.24 | 6.53 | 12.15 | 15.1 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | - | 0.05 | Upgrade
|
| Total Liabilities | 137.39 | 127.79 | 60.73 | 46.15 | 27.68 | 27.54 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | - | Upgrade
|
| Additional Paid-In Capital | 2,287 | 1,071 | 939.31 | 566.16 | 372.76 | - | Upgrade
|
| Retained Earnings | -790.81 | -570.76 | -358.54 | -184.55 | -66.54 | -22.19 | Upgrade
|
| Comprehensive Income & Other | 7.1 | 0.13 | -2.7 | -0.19 | -0.01 | -43.17 | Upgrade
|
| Total Common Equity | 1,503 | 500.76 | 578.08 | 381.43 | 306.22 | -65.36 | Upgrade
|
| Shareholders' Equity | 1,503 | 500.76 | 578.08 | 381.43 | 306.22 | 69.36 | Upgrade
|
| Total Liabilities & Equity | 1,641 | 628.56 | 638.8 | 427.58 | 333.9 | 96.91 | Upgrade
|
| Total Debt | 7.6 | 9.85 | 10.69 | 11.73 | 0.94 | 4.94 | Upgrade
|
| Net Cash (Debt) | 1,581 | 585.5 | 600.04 | 393.81 | 327.2 | 89.64 | Upgrade
|
| Net Cash Growth | 197.18% | -2.42% | 52.37% | 20.36% | 265.01% | - | Upgrade
|
| Net Cash Per Share | 16.06 | 8.02 | 11.50 | 9.51 | 15.10 | 33.04 | Upgrade
|
| Filing Date Shares Outstanding | 119.31 | 79.72 | 70.81 | 47.75 | 37.58 | 2.99 | Upgrade
|
| Total Common Shares Outstanding | 118.9 | 79.28 | 69.77 | 47.75 | 37.57 | 2.99 | Upgrade
|
| Working Capital | 1,531 | 530.63 | 571.03 | 381.48 | 317.09 | 85.44 | Upgrade
|
| Book Value Per Share | 12.64 | 6.32 | 8.29 | 7.99 | 8.15 | -21.87 | Upgrade
|
| Tangible Book Value | 1,503 | 500.76 | 578.08 | 381.43 | 306.22 | -65.36 | Upgrade
|
| Tangible Book Value Per Share | 12.64 | 6.32 | 8.29 | 7.99 | 8.15 | -21.87 | Upgrade
|
| Machinery | 15.34 | 13.31 | 9.13 | 6.29 | 3.03 | 1.86 | Upgrade
|
| Leasehold Improvements | 0.29 | 0.29 | 0.25 | 0.25 | 0.42 | 0.42 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.